Previous Article | Next Article ![]()
Journal of Virology, October 2004, p. 10543-10555, Vol. 78, No. 19
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.19.10543-10555.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Flavivirology Laboratory, Department of Microbiology, National University of Singapore, Singapore
Received 16 February 2004/ Accepted 18 April 2004
|
|
|---|
|
|
|---|
The family Flaviviridae are positive-sense, single-stranded RNA viruses that replicate in the cytoplasm of infected cells. Many members of the three genera (Flavivirus, Pestivirus, and Hepacivirus) belonging to this family are medically important human pathogens. The members of the genus Flavivirus are small (
50 nm), spherical enveloped particles and include many arthropod-transmitted human pathogens: West Nile virus (WNV), yellow fever virus, dengue virus, Japanese encephalitis virus, and tick-borne encephalitis virus (49). Flavivirus RNA genome encodes for three structural proteins (capsid [C], precursor of membrane [prM], and envelope [E]), and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) that are essential for intracellular replication of the virus (12, 13, 49, 58). The RNA genome is packaged within a spherical nucleocapsid that composed of multiple copies of the capsid proteins (11, 59). The nucleocapsid is further enwrapped by a modified lipid bilayer derived from host cellular membranes through the insertion of virus structural proteins, envelope, and precursor membrane. Cleavage of prM by cellular furin or related proteases during virus maturation pathway would then release matured virus particles containing M proteins (37).
The E protein of flaviviruses has been demonstrated to play crucial role in mediating virus-host cellular receptors interaction (17, 25, 26, 48, 53). Based on the crystallography data of the tick-borne encephalitis flavivirus E protein, Rey et al. (48) noted that each E-protein monomer is folded into three distinct structural domains. The central structural domain I is the antigenic domain that carries the N glycosylation site. Structural domain II of the E protein is believed to be responsible for pH-dependent fusion of the virus E protein to the endocytic vesicles membrane during uncoating and structural domain III is important for flavivirus binding to host cells. The structural domain III of E protein contains a fold typical of an immunoglobulin constant domain and postulated to form the receptor-binding site for the virus particles. A 105-kDa protease-sensitive, N-linked glycoprotein was recently determined to be the putative receptor for WNV infection in Vero and murine neuroblastoma 2A cells (16).
A previous study by Gollins and Porterfield (21) has briefly reported that WNV is internalized into macrophage-like cell line, P388D1 cells by using endocytosis. However, the exact internalization and trafficking pathways taken by flavivirus to gain access into host cells still remains unclear. The present study documents the entry of WNV from the point of attachment to internalization, the uncoating process and, finally, the release of the virus genome.
|
|
|---|
Antibodies and reagents. Mouse monoclonal antibodies against WNV (H546) were purchased from Microbix Biosystems, Inc. The antibody for WNV E protein was a monospecific polyclonal antibody, kindly provided by Vincent Deubel, Pasteur Institute, Paris, France. The anti-C protein antisera were a generous gift from Edwin G. Westaway, Sir Albert Sakzewski Virus Research Laboratory (Queensland, Australia). Mouse monoclonal antibodies to cellular proteins, clathrin, caveolin, early endosomal antigen 1 (EEA1), lysosomal-associated membrane protein 1 (LAMP1), and Bip (endoplasmic reticulum [ER] marker) were purchased from BD Pharmingen and anti-Golgi zone was purchased from Chemicon. The secondary antibodies conjugated to Texas red (TR) or fluorescein isothiocyanate (FITC) were purchased from Amersham Pharmacia Biotech. Lysotracker (a stain for late endosomes and lysosomes) was purchased from Molecular Probes. Fifteen- and ten-nanometer protein A-colloidal gold was purchased from Agar Aids. Monodanslycadervine, chlorpromazine, filipin, nocodazole, cytochalasin B, bafilomycin A, amantidine, chloroquine, and acridine orange were purchased from Sigma.
Transfections.
Plasmid constructs of dominant-negative Eps15 (GFP-E
95/295) was kindly provided by A. Benmerah, Pasteur Institute, and plasmid constructs backbone EGFP-C2 was purchased from Clontech. Unless stated otherwise, transfections were performed by using Lipofectamine Plus reagents from Invitrogen as specified by the manufacturer. In brief, Vero cells were grown on coverslips in 24-well tissue culture plate until 75% confluency. Then, 2.5-µg portions of the respective constructs was complexed with 4 µl of Plus reagent in 25 µl of OPTI-MEM medium (Gibco) for 15 min at room temperature. The mixture was then added to 25 µl of OPTI-MEM containing 2 µl of Lipofectamine. After incubation for another 15 min, the DNA-liposome complexes were added to the cells. After incubation for 3 h at 37°C, 1 ml of complete growth medium was added and incubated for another 24 h before virus entry assay was carried out.
Indirect immunofluorescence and confocal microscopy. For immunofluorescence microscopy, cell monolayers were first grown on coverslips till 75% confluency. The subsequent procedure is similar to that described in reference 15. The primary antibodies to clathrin, caveolin, EEA1, LAMP1, and Bip were used at concentrations of 0.25 and 0.2 µg/ml for anti-WNV antibodies. TR- or FITC-conjugated secondary antibodies were used at a concentration of 0.1 µg/ml. The specimens were then viewed with a laser scanning confocal inverted microscope (Leica TCS SP2) with an excitation wavelength of 543 nm for TR and 480 nm for FITC by using a x63 objective lens.
Negative staining of WNV preparation. For negative staining of WNV preparation, 10 µl of WNV was added to freshly glow discharged, carbon-coated grids, and stained with 2% uranyl acetate for 1 min. The grids were then air dried before viewing under the CM120 Biotwin transmission electron microscope (Philips).
Cryoimmunolabeling electron microscopy. Vero cells were incubated with WNV (MOI = 25) at 4°C for 30 min to allow synchronous virus attachment to the plasma membrane. Cells were then incubated for 1, 3, 5, 15, and 30 min at 37°C and processed for cryoelectron microscopy by the Tokuyasu method (54) with some modifications as described in Ng et al. (42). Briefly, the cells were fixed in 4% paraformaldehyde and 0.2% glutaraldehyde, followed by embedding in gelatin. The gelatin block with the cells was immersed in cryoprotectant, rapidly frozen before cryoultramicrotomy (UCT with the EM FCS Cryo-Attachment; Leica).
For immunolabeling (42), the primary antibodies, anti-EEA1, LAMP1, WNV C protein, and WNV E protein were used, followed by conjugation with protein A-colloidal gold (Agar Aids) at a dilution of 1:20. The sections were viewed under a CM120 Biotwin transmission electron microscope (Philips).
Preparation of digoxigenin-11-dUTP incorporated DNA probes. The DNA probes used for in situ hybridization were prepared as previously described by Grief et al. (22) and An et al. (1). The first-round PCR was performed with the oligonucleotide primers PE1 (5'-AGCTTCAACTGTTTAGGAATGA) and PE2 (5' CACCTTCCTGCGACCCTAGAG), which amplified a region of the viral E protein gene (784 bp) from plasmid pWNVE. Plasmid pWNVE was constructed by ligating the full-length E protein gene of WNV (Sarafend) into plasmid pcDNA3.1 (Invitrogen). The resulting amplified products were used for a second round and asymmetric PCR with primer PE3 (5'-GGAGTTATGCTGAACCTTCC) to generate the complementary (negative) single-stranded probes with the incorporation of digoxigenin-11-dUTP (Roche) (1). The incorporation of digoxigenin-11-dUTP was checked by immunospotting the probes onto nylon membrane as described in reference 1. To perform in situ hybridization on cryosections of cells, the DNA probes were first diluted in hybridization buffer, and hybridization was carried out as described in reference 22. After hybridization, the sections were viewed by using a CM120 Biotwin transmission electron microscope.
Percoll fractionation of cell homogenates. Vero cells were infected with 35S-labeled WNV at an MOI of 10 for 1 h at 4°C. Unbound virus was removed by two washes with phosphate-buffered saline (PBS). The cells were then allowed to internalize WNV for 5, 15, and 30 min at 37°C. At appropriate times after internalization of virus particles, the cells were washed twice with cold PBS before being detached by gentle scraping. After centrifugation for 10 min at 1,500 rpm, the cell pellet was resuspended in homogenization buffer (10 mM Tris-HCl, 0.2 mM sucrose, 1 mM EDTA, protease cocktail inhibitor [pH 7.4]). The suspension was subjected to 20 strokes in a tight-fitting homogenizer (Jensons). The homogenate was centrifuged for 10 min at 1,000 rpm (to remove the nuclei), and the postnuclear supernatant was collected. For the separation of subcellular particles in the postnuclear supernatant, an isosmotic solution of 20% Percoll was prepared as previously described (46). The postnuclear supernatant samples were centrifuged at 32,000 x g for 30 min in a Beckman 70.1 Ti rotor. Density marker beads (Pharmacia Biotech) were used as external standards for the density gradients in the Percoll solution. Fractions of 250 µl were collected and processed for liquid scintillation counting of 35S-labeled WNV radioactivity in a Beckman LS6500 liquid scintillation counter.
Virus entry assay and drug treatments. Vero cells growing on coverslips were incubated with WNV at an MOI of 10 for 1 h at 4°C with gentle rocking. Unbound virus was washed three times in ice-cold PBS and shifted to 37°C for 1 h in growth medium to allow virus penetration. Extracellular virus that failed to enter into cells was inactivated with sodium citrate buffer (pH 2.8) as described by Chu and Ng (16). Infected monolayers were washed twice with PBS and further incubated at 37°C for 24 h. At 1 day p.i., cells were fixed in methanol and processed for immunofluorescence assay as described above. The number of infected cells is scored in comparison to mock-infected cells.
To determine the effects of the drugs used to inhibit the entry of WNV, Vero cells were either pretreated with drugs (as listed below) for 1 h at 37°C, followed by virus infection, or the drugs were added at 10 min, 30 min, 1 h, or 2 h p.i. Cells were infected as described above and processed for immunofluorescence assay. Three independent experiments were carried out for each set of drugs used. The inhibition of virus entry was determined by determining the number of virus antigen-positive cells in relation to the total number of cells (virus antigen positive and negative) and is expressed as the percentage virus antigen-positive cells.
The drugs used in the present study were as follows: inhibitor of receptor-mediated endocytosis, monodanslycadervine (0.5 mM); inhibitors of clathrin function, chlorpromazine (5 µg/ml) and sucrose (0.3 M); inhibitor of caveola-dependent endocytosis, filipin (1 µg/ml); lysosomotropic drug, chloroquine (15 µM) and amantidine (0.5 µM); vacuolar-ATPase inhibitor, bafilomycin A1 (0.1 µM); and inhibitor of the endocytotic trafficking pathway, cytochalasin B (1 µg/ml) and nocodazole (5 µM).
|
|
|---|
|
View larger version (22K): [in a new window] |
FIG. 1. Localization study of WNV envelope protein in Vero cells during the infection cycle. At different times p.i. (a, 3 min; b, 10 min; c, 30 min; d, 4 h; e, 12 h), Vero cells were fixed and processed for immunofluorescence assay. WNV E protein was detected with polyclonal anti-WNV E protein and with anti-rabbit antibodies conjugated with FITC as the secondary antibody.
|
![]() View larger version (151K): [in a new window] |
FIG. 2. Ultrastructural analysis of WNV entry process by using immunocryoelectron microscopy. (a) Homogeneous population of negatively stained WNV particles. (b) Binding of WNV particle at the plasma membrane of Vero cells. (c) Uptake of WNV particle (arrow) by coated pit (arrowheads). (d) WNV particle (arrow) is internalized within a clathrin-coated pit as indicated by the 10-nm gold particles. (e) Localization of single WNV particle in endocytic vesicles. (f) Fusion of WNV (black arrows) containing endocytotic vesicles (white arrows) that formed multivirus-containing compartments. (g) Multivirus-containing endocytotic vesicles are found in close proximity to the ER compartments. Virus particles are indicated by arrows. (h) Fusion of the WNV particle (arrows) with the endocytotic vesicle membrane. (i) Expulsion of the nucleocapsid of WNV (arrows) after fusion of the viral envelope with the endocytotic membrane. (j) Immunodetection of WNV nucleocapsid particles in the cytoplasm with gold particles conjugated to anti-capsid serum. Bars represent 100 nm (a to d) 200 nm (f, g, and j), 50 nm (e and j, inset), or 100 nm (h).
|
After 5 min at 37°C, most of the virus particles are observed within endocytic vesicles. Single virus particle was contained within each of these vesicles (Fig. 2e). By 10 min, vesicles containing single virus particle (Fig. 2f, black arrows) are seen fusing with one another (Fig. 2f, white arrows) resulting in the formation of large electron-lucent vesicles (
500 nm in diameter) containing several virus particles. These virus-containing vesicles are predominantly localized to the perinuclear region in close association with the ER. WNV particles are indicated by the arrows (Fig. 2g). Thus far, it has been a challenge to visualize the uncoating process of flaviviruses in endocytic vesicles. It is believed that the acidification of the endocytic vesicles would cause the fusion of the viral envelope protein with the endocytic vesicle membrane and triggered the release of the flavivirus nucleocapsid into the cytoplasm. Figure 2h and i show the fusion process of WNV particles with the endocytic vesicle membrane (by 15 min) to expel the viral RNA-containing nucleocapsids into the cytosol. In Fig. 2 h, the viral envelope has loosened and fused with the endocytic vesicles membrane (arrow). Figure 2i shows the release of the viral nucleocapsid (arrow) after fusion with the membrane of the endocytic vesicle. With the superiority of cryofixation procedure, released viral nucleocapsid particles in the cytoplasm was visualized in the present study. Nucleocapsid particles (arrows [labeled by anti-WNV capsid antibodies conjugated to 10-nm gold particles]) were observed in proximity with the endocytic vesicles and the ER region (Fig. 2j). The inset shows a higher magnification of the boxed area.
To investigate the location of the viral RNA genome upon release from the nucleocapsid, in situ hybridization with digoxigenin-11-dUTP (DGdUTP)-incorporated DNA probes coupled with cryoimmunoelectron microscopy were used. Hybridization of the synthesized cDNA probe to the viral RNA was detected by using anti-digoxigenin, which was further conjugated with 10-nm gold particles. The specificity of the synthesized DNA probes binding to the viral RNA was assessed. No hybridization signal (absence of gold particle decoration) was detected when cryosections of uninfected Vero cells were incubated with the synthesized DNA probes (results not shown). In addition, hybridization signals were not detected for RNase-treated cryosections of WNV-infected cells (data not shown). For WNV-infected cells, viral RNA (as indicated by the 10-nm gold particles) was found in close proximity with the ER after 20 min at 37°C (Fig. 3). Virus particles were no longer detectable within the endocytic vesicles that were located near the ER, as previously observed in Fig. 2g and h. This observation is consistent with previous studies that have documented that the ER is the site of flavivirus replication (40, 41, 60).
![]() View larger version (103K): [in a new window] |
FIG. 3. The uncoated WNV RNA genome is associated with the ER. WNV RNA genome was detected by using immunogold labeling against DGdUTP (black arrows) that are incorporated into the DNA probes. Bar, 50 nm.
|
At 3 to 5 min after cells were warmed to 37°C, a double-labeled immunofluorescence assay with anti-WNV envelope protein and anti-EEA1 antibodies showed colocalization, suggesting that the virus particles were translocated to the endosomes after endocytosis. At these times, most of the virus-containing endosomes were distributed closer to the cell periphery (Fig. 4a). Similarly, WNV particles were seen within early endosomes, as indicated by the 10-nm gold particles bound to antibodies against EEA1 by using immunogold-labeled electron microscopy (Fig. 4d). By 12 min after a shift up to 37°C, WNVs are found mainly in vesicles (Fig. 4b) that were stained with Lysotracker (Molecular Probes), suggesting that WNV were localized to the late endosomes and lysosomes by this time point. The fluorescent staining was more intense at the perinuclear region. A unique accumulation of a large number of virus-containing late endosomes and lysosomes were observed at the perinuclear region by 15 min (Fig. 4c, white arrow), and these structures remained until 30 min p.i. (data not shown). Immunogold labeling electron microscopy further confirmed the identity of these virus-containing vesicles as lysosomes. Gold particles (white arrowheads; 15 nm in diameter) binding to antibodies against LAMP1 were localized around the lysosomal membrane. The antibodies to envelope proteins of the WNV were also labeled with 10-nm gold particles (arrows). Several virus particles with loosened envelope and fusion with the lysosomal membrane can be observed (Fig. 4e). In addition, attempts were made to localize the distribution of viral nucleocapsid in the cytoplasm after uncoating. Viral capsid proteins were observed to colocalize strongly (yellow staining) with the cellular marker (BiP) for ER (Fig. 4f) but not the Golgi complex in a double-labeled immunofluorescence assay (data not shown).
![]() View larger version (79K): [in a new window] |
FIG.4. Colocalization of WNV with early and late endocytic vesicles markers. (a) Anti-EEA1 was used to stain the early endosomes at 5 min p.i. Lysotracker (b) and anti-LAMP1 (c) were used to stain late endosomes and lysosomes at 12 and 15 min p.i., respectively. EEA1 and LAMP1 antibodies are conjugated with Texas Red (TR), and WNV E protein antibody is conjugated with FITC. (d) A WNV particle (arrow) is localized within early endosomes, as indicated by gold particles conjugated to anti-EEA1 antibodies. (e) LAMP1-positive lysosome (gold particles [arrowheads]) containing large number of WNV particles (arrows) can be seen in close association with the ER. The virus particles are decorated with gold particles conjugated with anti-WNV E protein. (f) Colocalization of WNV nucleocapsids with ER marker. Anti-BiP and anti-capsid sera are used to stain the ER and nucleocapsid, respectively. WNV nucleocapsids were localized to the ER. BiP marker is conjugated with TR, and capsid protein antibody is conjugated with FITC. Bars (d and e), 50 nm. NU, nucleus.
|
Pretreatments of Vero cells with monodanslycadervine, chlorpromazine, and sucrose for 1 h before WNV infection or administration of these drugs at 10 min p.i. significantly reduced the number of infected cells. However, monodanslycadervine, chlorpromazine, and sucrose did not seem to exert any inhibitory effect on WNV infection when these drugs were added 1 and 2 h p.i. This result suggested that these drugs selectively blocked an early step in the entry process of WNV (Fig. 5a, b, and c, respectively). In contrast, filipin had no significant effect on WNV infection regardless of the timing of the drug added to the cells (Fig. 5d).
![]() View larger version (67K): [in a new window] |
FIG. 5. Effects of clathrin-mediated endocytosis-disrupting drugs on WNV entry into Vero cells. The percentage of viral antigen-positive cells was plotted against time. Cells treated with monodanslycadervine (a), chlorpromazine (b), or sucrose (c) showed marked reduction in WNV entry, whereas filipin (d) does not significantly inhibit virus entry. The average of three independent experiments is shown.
|
In this part of the study, Vero cells were first transfected with either GFP-E
95/295 plasmid (dominant-negative mutant) or EGFP-C2 plasmid (coding for green fluorescent protein [GFP] as an internal control) as previously described by (6). Transfected cells were then assayed for their capacity to internalize TR-conjugated transferrin and WNV. The internalization of TR-transferrin was impaired in cells expressing GFP-E
95/295, but not in cells that express GFP, when visualized under a confocal scanning laser microscope (data not shown).
As shown in Fig. 6a, the uptake of WNV was drastically reduced in cells transfected with GFP-E
95/295 plasmid compared to cells that were transfected with EGFP-C2 plasmid alone or to mock-transfected Vero cells. GFP-E
95/295 expressing cells are also incubated with WNV at 37°C for 30 min and processed for immunofluorescence staining and confocal microscopy. WNV particles (stained by anti-WNV E protein antibodies conjugated to TR [arrows]) were observed to attach and accumulate exclusively on the plasma membrane but failed to enter the cells (Fig. 6b, arrows). In contrast, Fig. 6c shows the internalization of WNV (arrows, speckled staining) within the cytoplasm of GFP-expressing cells. These results together provide strong evidence that WNV entry into cells takes place through clathrin-mediated endocytosis.
![]() View larger version (57K): [in a new window] |
FIG. 6. Inhibition of WNV entry into Vero cells expressing Eps15 dominant-negative mutant protein. (a) The entry of WNV was significantly inhibited in Vero cells transfected with GFP-E 95/295. The number of viral E antigen-positive cells in relation to the total cell population is expressed as a percentage of viral antigen-positive cells. (b) Binding of WNV (stained with TR [arrows]) on the plasma membrane of the GFP-E 95/295-expressing cell was observed but no internalization of the virus particles occurred. (c) Internalized WNV particles (arrows) are observed within cells expressing the negative control plasmid expressing GFP.
|
![]() View larger version (22K): [in a new window] |
FIG. 7. Cytochalasin D- and nocodazole-pretreated Vero cells inhibit entry of WNV. The percentage of viral antigen-positive cells is plotted against time. A dose-dependent inhibition of WNV internalization into cytochalasin D (a)- and nocodazole (b)-treated Vero cells is observed. The average of three independent experiments is shown.
|
In this experiment, Vero cells were either pretreated with cytochalasin D (2 µg/ml) or nocodazole (40 µM) for 1 h before incubation with 35S-radiolabeled WNV at an MOI of 10. At 30 min p.i., the WNV-infected cells were subjected to homogenization, followed by fractionation in a Percoll gradient. A total of 24 fractions were collected and analyzed for radioactivity counting. For the untreated Vero cells, two peaks of radioactivity were detected (Fig. 8b). The densities of the radioactive peaks were determined relative to the density bead makers based on their positions in the Percoll gradient as shown in Fig. 8a. The density of the first peak corresponded closely to the endosomal marker fraction (1.034 g/ml), whereas the second peak was in the vicinity of the lysosomal marker fraction (1.075 g/ml). For the nocodazole-treated cells, the radioactive WNV particles were observed in a single density fraction that corresponded to the early endosome marker fraction (1.034 g/ml; Fig. 8c). Hence, the intact microtubules network is indeed necessary for the trafficking of the internalized WNV from early to late endosomes. As for the cytochalasin D-treated cells, a single radioactive peak was detected, and this peak corresponded to the plasma membrane marker fraction (density of 1.045 g/ml; Fig. 8d), suggesting that the perturbation of actin filaments might have prevented internalization of the attached virus particles on the plasma membrane.
![]() View larger version (36K): [in a new window] |
FIG. 8. Subcellular fractionations of cellular homogenates from WNV-infected cells in 20% Percoll gradients. (a) Standard plot of density distribution determined by density marker beads in the 20% Percoll gradient. (b) Vero cells are allowed to internalized radiolabeled WNV at an MOI of 10 for 30 min and subjected to cellular fractionation. (c and d) A procedure similar to that for panel b was carried out except that the Vero cells were pretreated (1 h) with nocodazole and cytochalasin D, respectively.
|
For untreated Vero cells, granular orange fluorescence was observed (Fig. 9a), and this is consistent with the descriptions reported by Nawa (38) and Umata et al. (55). The granular orange fluorescence was totally abolished in cells that were treated with 1.5 µM chloroquine (Fig. 9b), 1 µM amantidine, and 0.5 µM bafilomycin A (data not shown). To analyze the effect of chloroquine, amantidine, and bafilomycin A on the entry mechanism of WNV, Vero cells were pretreated with increasing noncytotoxic concentrations of each drugs, followed by WNV infection.
![]() View larger version (49K): [in a new window] |
FIG. 9. pH-dependent entry pathway of WNV into Vero cells. (a and b) Acridine orange staining of untreated Vero cells (a) and cells after incubation with 1.5 µM chloroquine (b). Acridine orange staining of acidic vesicles in chloroquine-treated cells (a) was abolished compared to the untreated cells (b). Inhibitory effect on the entry of WNV into pretreated Vero cells with bafilomycin A (c), chloroquine (d), and amantidine (e). A dose-response inhibition of WNV entry was observed for all three of the drugs used. The average of three independent experiments is shown.
|
|
|
|---|
In the present study, a variety of experimental approaches was utilized to study the detail entry pathway taken by flavivirus WN during the early events of infection. The entry process of WNV into Vero cells began with the attachment of the virus particles at the cell surface (Fig. 2b), which is followed by a clathrin-mediated endocytic pathway to internalize WNV particles (Fig. 2c to e). WNVs are then trafficked along an endosomal and lysosomal endocytic pathway (Fig. 2e to h and 4b and c) with the involvement microtubules network and, subsequently, a pH-dependent fusion mechanism to expel the viral nucleocapsid into the cytoplasm in close proximity to the ER (Fig. 2i and j, 3, and 4e and f).
Beasley and Barrett (5) have recently identified neutralizing epitopes within structural domain III of the WNV E protein and concluded that the structural domain III is the likely receptor-binding domain. The cellular counterpart of domain III has also recently identified as a 105-kDa plasma membrane-associated protein by Chu and Ng (16).
Upon attachment of WNV to the cell surface, WNV particles are internalized within 2 to 3 min after the temperature shift from 0 to 37°C (Fig. 2c). As illustrated ultrastructurally with immunogold labeling against anti-clathrin antibodies on cryosections, WNVs are localized within clathrin-coated pits (Fig. 2d). To further confirm that WNVs are being internalized by clathrin-mediated endocytosis, Vero cells were treated with pharmacological agents (monodanslycadervine, chlorpromazine, and sucrose Fig. 5a to c) that inhibit receptor-mediated endocytosis and clathrin functions. Chlorpromazine has been extensively used to study virus entry. Involvement of clathrin-mediated endocytosis of influenza virus (32), polyomavirus JC virus (45), picornavirus parechovirus type I (29), and the Japanese encephalitis virus (39) was demonstrated with the actions of chlorpromazine. Chlorpromazine acts by accumulating clathrin and AP-2 in endosomal compartments, hence preventing the formation of clathrin-coated pits at the plasma membrane.
High concentrations of sucrose can also be used to inhibit clathrin-mediated endocytosis by inducing hypertonicity that deplete potassium ions, thus causing clathrin to dissociate (8). The involvement of clathrin in human rhinovirus infection and Hantaan virus infection was illustrated by potassium depletion studies (28, 4). The WNV internalization was significantly inhibited when Vero cells were pretreated with noncytotoxic concentrations of chlorpromazine and sucrose (Fig. 5b and c). In contrast, filipin (which inhibits caveola-dependent endocytosis) did not significantly affect WNV infection (Fig. 5d). These results were further supported by the finding determined by immunofluorescence assay that WNV colocalized with clathrin but not caveolin (data not shown).
The formation of clathrin-coated pits at the plasma membrane during the process of receptor-mediated endocytosis requires the interaction of clathrin, along with its accessory factors (57). These accessory factors serve important roles in the regulatory and catalytic mechanism at specific stages in clathrin-mediated endocytosis. One of the newly discovered accessory factors, Eps15 is ubiquitously and constitutively associated with AP-2 for the formation of clathrin-coated pits at the plasma membrane. Studies by Carbone et al. (10) and Benmerah et al. (6) showed that the overexpression or microinjection of dominant-negative mutants of Eps15 strongly inhibits clathrin-dependent endocytosis. Expression of dominant-negative Eps15 in Vero cells demonstrated strong inhibition of WNV uptake (Fig. 6). It was also noted that the inhibition of clathrin-coated pits formation at the plasma membrane did not affect the binding of WNV particles to the cell surface, as revealed by immunofluorescence assay (Fig. 6b). The data thus far provide strong evidence that the initial internalization of WNV after attaching to the plasma membrane proceeds by clathrin-mediated endocytosis.
After internalization by clathrin-mediated endocytosis, the virus particles are trafficked along the cellular endocytic pathway. The endocytic pathway also serve as a rapid transit system in the delivery of viral cargo to specific locations within cells for its replication. At present, two principle postinternalization endocytic trafficking routes are known: recycling or the lysosome-targeted pathway (23). For the latter, acidification within the vesicles is one characteristic of the endocytic pathway. This process has been shown to be essential for the uncoating of many enveloped viruses. Viruses such as adeno-associated viruses (3) and human rhinovirus HRV14 (4) have been shown to escape or undergo uncoating in early endosomes, whereas many other viruses (poliovirus type 1 and mouse Elberfeld virus) are trafficked from early endosomes to late endosomes and then to lysosomes for uncoating (62).
By 5 min after internalization, most WNVs are observed singly within endocytic vesicles, and these vesicles are identified as early endosomes based on morphological characteristics and immunolabeling with the cellular marker EEA1 (Fig. 2e and 4a). Colocalization of WNV- with LAMP1-positive vesicles was observed by 15 min after entry (Fig. 4c). The trafficking process of WNV along the endocytic pathway seemed to occur rapidly (within 15 min of attachment) and was consistent with the speed of typical trafficking of cellular ligands such as transferrin or epidermal growth factor that utilized clathrin-mediated endocytosis (31, 35). The trafficking-maturation model of endosomes has suggested that endosomes act as transient independent carriers that progressively change in size and shape by homologous fusion and eventually mature into late endosomes and lysosomes (23, 52). This was also observed in the trafficking of WNV; endosomes containing single WNV particles were observed to fuse with each other, resulting in the formation of large endocytic vesicles (late endosomes and lysosomes) that contained several virus particles (Fig. 2f and g and 4b and c). Therefore, the data showed that after the internalization of WNV by clathrin-mediated endocytosis, the virus particles were trafficked through the endosomes and eventually to the late endosomes and lysosomes.
Host cytoskeleton, namely, the actin filaments and microtubules, has been observed to be involved in the trafficking of endocytic compartments containing internalized ligand-receptor complexes. Actin filaments are required for the initial uptake of ligands and subsequent degradative pathway, whereas microtubules are involved in maintaining the endosomal traffic between peripheral early and late endosomes (19). Recent evidence has suggested that actin cytoskeleton is closely associated with clathrin-coated pits and that actin polymerization may be involved in moving endocytic vesicles into cytosol after they are pinched off from the plasma membrane (47). The actin-binding molecular motor, myosin VI, was also recently shown to mediate clathrin endocytosis (9). Disruption of actin filaments can have a dramatic effect on receptor-mediated endocytosis. Cytochalasin D, an actin-disrupting drug, specifically affects the actin cytoskeleton by preventing its proper polymerization into microfilaments and promoting microfilament disassembly (20).
On the other hand, microtubules are required for efficient transcytosis and for trafficking endosomes to late endosomes and lysosomes. Nocodazole disrupts microtubules by binding to ß-tubulin and preventing formation of one of the two interchain disulfide linkages, thus inhibiting microtubules dynamics (56). It appears noteworthy that the endocytic pathway for WNV is closely associated with host cells cytoskeleton network. As revealed by Percoll cell fractionation studies, the initial internalization of WNV that have attached to the plasma membrane was affected for Vero cells that were pretreated with cytochalasin D (Fig. 8). WNVs are predominantly detected in the plasma membrane fraction instead of the endosomal fraction, suggesting the early involvement of actin filaments in clathrin-mediated endocytosis. In contrast, the initial internalization of WNV via clathrin-coated pits was not affected with cells treated with nocodazole. However, WNV accumulated in endosomes and trafficking of the virus particles to lysosomes was deterred in nocodazole-treated cells (Fig. 8).
It is also notable that incubation of cells with lysosomotropic weak bases (chloroquine and amantidine) and vacuolar H+-ATPase (VATPase) inhibitor (bafilomycin) caused a marked reduction in the entry of WNV. This observation is consistent with a number of enveloped viruses that are currently considered to be pH dependent for the uncoating process along endocytic vesicles (30). For flaviviruses, it has been proposed that the structural domain II of the E protein require a pH-dependent fusion at the endocytic membranes. Mutational studies that disrupt the functional biology of this domain have shown a decrease in the virulence of these flaviviruses (36). A highly conserved amino acid cluster located at the tip of domain II has been proposed to be the internal fusion peptide. At the pH of fusion, the flavivirus E protein on the surface of the virus undergo irreversible conformational changes to expose the fusion peptide for interaction with the target membrane (24).
Ultrastructural analysis and immunofluorescence assays have indicated that the pH-dependent fusion of WNV E protein occurs predominantly within lysosomes. The fusion process of the WNV E protein with the lysosomal membrane was observed by using cryoimmunoelectron microscopy, and the uncoated nucleocapsid particles were then released into the cytoplasm in the vicinity of the ER (Fig. 2j). Thus far, entry studies of flaviviruses have not been able to visualize the presence of nucleocapsid particles in the cytoplasm after the release from endocytic vesicles. It has been suggested by Gollins and Porterfield (21) that the uncoated nucleocapsids undergo spontaneous dissociation upon exit into the cytoplasm due to the instability of capsid protein interactions. However, in the present study, the released nucleocapsids in the cytoplasm were imaged and identified for the first time. The released nucleocapsids were labeled with gold particles and were observed in close association with the lysosomes and ER region (Fig. 2j and 4f).
To confirm the specific location of the release WNV RNA genomes, in situ hybridization coupled with immunoelectron microscopy were used. The viral RNA genomes were found to localize in the proximity of ER region (Fig. 3). The signal required for the trafficking of the released viral RNA genome after uncoating to the ER is still not known. Additional studies are under way to elucidate this trafficking mechanism.
The entry pathway of WNV was mapped. WNV utilizes various cellular components to facilitate its trafficking to specific sites in the cell so that a successful infection can occur. Understanding the entry pathway of flavivirus can serve as an important platform for the future development of antiviral strategies and for the screening antiviral agents.
This study was supported by a grant from the Biomedical Research Council (project 01/1/21/18/003).
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»